High tumour mutation burden improves overall survival in solid tumours treated with immune checkpoint inhibitors
High Mutation Counts May Predict Better Cancer Survival Outcomes
This systematic review and meta-analysis evaluated 5278 patients with solid tumours treated with immune checkpoint inhibitors or chemotherap…
High mutation counts in tumors may help predict who will survive longer when taking powerful immune-boosting cancer drugs
CT-based immune radiomic signature shows association with prognosis in non-small cell lung cancer
CT scans may help predict lung cancer treatment response
This cohort study utilized a CT-based immune radiomic signature, known as CT-RadScore, across multiple patient cohorts including TCIA, TCGA,…
A new way to analyze CT scans could help doctors predict how lung cancer patients respond to immunotherapy and other drugs.
CIPHER model predicts immune checkpoint inhibitor pneumonitis risk in non-small cell lung cancer patients
Lung Scans Can Now Predict Dangerous Side Effect Before Treatment
This cohort study evaluated a CIPHER model versus classical radiomic models for predicting immune checkpoint inhibitor-induced pneumonitis i…
This tool could help doctors protect patients before a serious side effect strikes.
Narrative review discusses tumor draining lymph nodes as a target for NSCLC therapy.
Lymph Nodes Hold Key to Beating Lung Cancer
This narrative review examines the tumor draining lymph nodes (TDLN) microenvironment remodeling in non-small cell lung cancer (NSCLC). The …
You wake up, sip your coffee, and take your morning walk.
Narrative review examines abscopal effect potential in non-small cell lung cancer multimodality therapies.
When One Tumor Shrinks, Others Can Too—Here’s How
This narrative review evaluates the abscopal effect in non-small cell lung cancer patients treated with radiotherapy, lung ablation, or immu…
A new review explains how treating one lung tumor can help shrink tumors elsewhere in the body, offering a new way to think about cancer tre…
Review of 68Ga-Pentixafor PET/CT Utility in Lung Cancer Diagnosis and Management
Lung Scans Get Smarter With New Imaging Tool
This narrative review examines the utility of 68Ga-Pentixafor PET/CT in patients with lung cancer. The authors synthesize evidence regarding…
You wake up, cough again — just like the past few weeks.
Preoperative inflammatory markers linked to survival in resectable NSCLC
Simple Blood Work Could Predict Lung Cancer Surgery Outcomes
This retrospective cohort study of 460 patients with resectable non-small cell lung cancer found that elevated preoperative inflammatory mar…
A new look at blood tests shows inflammation levels may help doctors plan better care for lung cancer patients.
Narrative review discusses osimertinib use in EGFR-mutated NSCLC patients with TKI resistance
Osimertinib may help some lung cancer patients after resistance develops
This narrative review examines the use of osimertinib and other EGFR-TKIs in non-small cell lung cancer patients harboring EGFR mutations af…
A review suggests osimertinib could be an option for non-small cell lung cancer patients with EGFR mutations who develop resistance to earli…
Meta-analysis shows local consolidative therapy plus systemic therapy improves survival in driver-negative oligometastatic NSCLC.
For a specific lung cancer group, adding local treatment to standard drugs significantly improved survival time.
This systematic review and meta-analysis evaluated local consolidative therapy combined with systemic therapy versus systemic therapy alone …
Adding local treatment to standard drugs significantly improved survival time for a specific lung cancer group with spread to only a few pla…
Narrative review examines driver mutations and immunotherapy response in non-small cell lung cancer
Does your lung cancer's genetic makeup change how well immune therapy works?
This narrative review explores how targetable driver gene alterations in non-small cell lung cancer (NSCLC) influence the tumor immune micro…
Lung cancer's genetic drivers actively reshape the tumor's immune environment, causing immunotherapy to work differently depending on a pati…
Case Report Details Aumolertinib Rechallenge Following Osimertinib-Induced Interstitial Lung Disease in Lung Adenocarcinoma
Can lung cancer drugs be restarted after severe lung injury?
This case report describes a 73-year-old male with stage IV lung adenocarcinoma and EGFR exon 19 deletions who experienced interstitial lung…
Doctors successfully restarted a powerful lung cancer drug after a patient's lungs healed from a dangerous reaction to the first one.
Combined radiomics classifier predicts 3-year recurrence in surgically resected stage IA-IIIA non-small cell lung cancer
Lung Cancer Relapse Risk Seen Earlier on Routine Scans
This cohort study evaluated a pre-surgical CT-based habitat-based radiomics classifier in 293 surgically resected non-small cell lung cancer…
A new scan method spots hidden tumor patterns that predict lung cancer relapse risk long before the disease returns.